 | Up a level |
Journal Article
Gratwohl, A., Pfirrmann, M., Zander, A., Kroger, N., Beelen, D., Novotny, J., Nerl, C., Scheid, C., Spiekermann, K., Mayer, J., Sayer, H. G., Falge, C., Bunjes, D., Doehner, H., Ganser, A., Schmidt-Wolf, I., Schwerdtfeger, R., Baurmann, H., Kuse, R., Schmitz, N., Wehmeier, A., Fischer, J. Th, Ho, A. D., Wilhelm, M., Goebeler, M-E, Lindemann, H. W., Bormann, M., Hertenstein, B., Schlimok, G., Baerlocher, G. M., Aul, C., Pfreundschuh, M., Fabian, M., Staib, P., Edinger, M., Schatz, M., Fauser, A., Arnold, R., Kindler, T., Wulf, G., Rosselet, A., Hellmann, A., Schaefer, E., Pruemmer, O., Schenk, M., Hasford, J., Heimpel, H., Hossfeld, D. K., Kolb, H-J, Buesche, G., Haferlach, C., Schnittger, S., Mueller, M. C., Reiter, A., Berger, U., Saussele, S., Hochhaus, A. and Hehlmann, R. (2016). Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment. Leukemia, 30 (3). S. 562 - 570. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
Hehlmann, R., Lauseker, M., Saussele, S., Pfirrmann, M., Krause, S., Kolb, H-J, Neubauer, A., Hossfeld, D. K., Nerl, C., Gratwohl, A., Baerlocher, G. M., Heim, D., Fabarius, A., Haferlach, C., Schlegelberger, B., Mueller, M. C., Jeromin, S., Proetel, U., Kohlbrenner, K., Burchert, A., Voskanyan, A., Rinaldetti, S., Goebeler, M., Dengler, J., Ho, A., Falge, C., Kanz, L., Kneba, M., Stegelmann, F., Pfreundschuh, M., Waller, C. F., Spiekermann, K., Fuchs, R., Scheid, C., Haenel, M., Koehne, C-H, Bruemmendorf, H., Lindemann, H-W, Berdel, W. E., Staib, P., Balleisen, L., Brossart, P., Schenk, M., Zankovich, R., Geer, T., Hertenstein, B., Bildat, S., Hochhaus, A. and Hasford, J. (2017). ASSESSMENT OF IMATINIB 400MG AS FIRST LINE TREATMENT OF CHRONIC MYELOID LEUKEMIA: 10-YEAR SURVIVAL RESULTS OF THE RANDOMIZED CML STUDY IV. Haematologica, 102. S. 151 - 153. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Hehlmann, R., Lauseker, M., Saussele, S., Pfirrmann, M., Krause, S., Kolb, H. J., Neubauer, A., Hossfeld, D. K., Nerl, C., Gratwohl, A., Baerlocher, G. M., Heim, D., Bruemmendorf, T. H., Fabarius, A., Haferlach, C., Schlegelberger, B., Mueller, M. C., Jeromin, S., Proetel, U., Kohlbrenner, K., Voskanyan, A., Rinaldetti, S., Seifarth, W., Spiess, B., Balleisen, L., Goebeler, M. C., Haenel, M., Ho, A., Dengler, J., Falge, C., Kanz, L., Kremers, S., Burchert, A., Kneba, M., Stegelmann, F., Koehne, C. A., Lindemann, H. W., Waller, C. F., Pfreundschuh, M., Spiekermann, K., Berdel, W. E., Mueller, L., Edinger, M., Mayer, J., Beelen, D. W., Bentz, M., Link, H., Hertenstein, B., Fuchs, R., Wernli, M., Schlegel, F., Schlag, R., de Wit, M., Truemper, L., Hebart, H., Hahn, M., Thomalla, J., Scheid, C., Schafhausen, P., Verbeek, W., Eckart, M. J., Gassmann, W., Pezzutto, A., Schenk, M., Brossart, P., Geer, T., Bildat, S., Schaefer, E., Hochhaus, A. and Hasford, J. (2017). Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia, 31 (11). S. 2398 - 2407. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
Hermann, B., Lehners, N., Brodhun, M., Boden, K., Hochhaus, A., Kochanek, M., Meckel, K., Mayer, K., Rachow, T., Rieger, C., Schalk, E., Weber, T., Schmeier-Juerchott, A., Schlattmann, P., Teschner, D. and von Lilienfeld-Toal, M. (2017). Influenza virus infections in patients with malignancies - characteristics and outcome of the season 2014/15. A survey conducted by the Infectious Diseases Working Party (AGIHO) of the German Society of Haematology and Medical Oncology (DGHO). Eur. J. Clin. Microbiol. Infect. Dis., 36 (3). S. 565 - 574. NEW YORK: SPRINGER. ISSN 1435-4373
Hoehler, T., von Wichert, G., Schimanski, C., Kanzler, S., Moehler, M. H., Hinke, A., Seufferlein, T., Siebler, J., Hochhaus, A., Arnold, D., Hallek, M., Hofheinz, R. and Hacker, U. T. (2013). Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205. Br. J. Cancer, 109 (6). S. 1408 - 1414. LONDON: NATURE PUBLISHING GROUP. ISSN 1532-1827
Stegelmann, F., Bangerter, M., Griesshammer, M., Hebart, H., Heidel, F., Hochhaus, A., Moehle, R., Reiter, A., Scheid, C., Kirschbaum, R., Reim, R., Sutter, U., Doehner, H., Schlenk, R. F. and Doehner, K. (2015). A phase-Ib/II study of ruxolitinib plus pomalidomide in Myelofibrosis: Data from the MPNSG-0212 Trial (NCT01644110). Oncol. Res. Treat., 38. S. 216 - 218. BASEL: KARGER. ISSN 2296-5262
Stegelmann, F., Griesshammer, M., Koschmieder, S., Reiter, A., Hochhaus, A., Heidel, F., von, Bubnoff N., Kindler, T., Hebart, H., Bangerter, M., Wolleschak, D., Moehle, R., Scheid, C., Reim, R., Sutter, U., Vetter, K., Doehner, H. and Doehner, K. (2017). Pomalidomide plus ruxolitinib in myelofibrosis: Updated results from the MPNSG-0212 trial. Oncol. Res. Treat., 40. S. 149 - 150. BASEL: KARGER. ISSN 2296-5262
Stegelmann, F., Griesshammer, M., Koschmieder, S., Reiter, A., Hochhaus, A., Heidel, F., von Bubnoff, N., Kindler, T., Hebart, H., Bangerter, M., Wolleschak, D., Moehle, R., Scheid, C., Reim, R., Sutter, U., Vetter, K., Doehner, H. and Doehner, K. (2017). COMBINATION THERAPY OF POMALIDOMIDE PLUS RUXOLITINIB IN MYELOFIBROSIS: RESULTS FROM COHORT 1 OF THE MPNSG-0212 TRIAL (NCT01644110). Haematologica, 102. S. 280 - 281. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Stegelmann, F., Hebart, H., Bangerter, M., Wolleschak, D., Griesshammer, M., Koschmieder, S., Hochhaus, A., Heidel, F., Moehle, R., Reiter, A., Scheid, C., von Bubnoff, N., Kirschbaum, R., Reim, R., Sutter, U., Vetter, K., Doehner, H., Schlenk, R. F. and Doehner, K. (2016). Ruxolitinib/Pomalidomide combination therapy in myelofibrosis: Current data from the MPNSG-0212 trial. Oncol. Res. Treat., 39. S. 233 - 235. BASEL: KARGER. ISSN 2296-5262
Teschner, D., Hermann, B., Lehners, N., Brodhun, M., Hochhaus, A., Boden, K., Kochanek, M., Meckel, K., Mayer, K., Rachow, T., Rieger, C., Schalk, E., Schmeier-Juerchott, A., Weber, T., Schlattmann, P. and von Lilienfeld-Toal, M. (2016). Influenza virus infections in patients with malignancies: Characteristics and outcome of the spring season 2015-final analysis by the infectious diseases working party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO). Oncol. Res. Treat., 39. S. 208 - 209. BASEL: KARGER. ISSN 2296-5262